Pharma: Clinic Roundup
Friday, June 29, 2012
Shire plc, of Dublin, Ireland, reported data showing that Vpriv (velaglucerase alfa for injection), its enzyme replacement therapy for Type I Gaucher disease, significantly improved selected markers of Gaucher-related bone disease in patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.